← FDA Drug Approvals (Drugs@FDA)

REVUFORJ

NDA · New Drug Application · Sponsor: SYNDAX · Approved 2024-11-15

Drug application

FDA Application #

NDA218944

Application type

New Drug Application

Brand name

REVUFORJ

Generic name

REVUMENIB

Active ingredients

REVUMENIB CITRATE

Dosage form

TABLET

Route

ORAL

Marketing status

Prescription

Sponsor

SYNDAX

Manufacturer

Syndax Pharmaceuticals, Inc.

First approval

2024-11-15

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown